This article is educational and does not replace medical advice. Prescription medication requires review by a licensed clinician and, when appropriate, a valid prescription. Compounded medications are not FDA-approved, and the FDA does not verify their safety, effectiveness or quality before marketing. Treatment eligibility is an individual clinical decision.
Released: ·Last reviewed: ·Methodology v4.1
This page is maintained. Prices are re-read at source and dated; evidence is checked against the published trial. Newest across the site: news · research · corrections.
Microdose GLP-1 safety
Quick answer
Lower GLP-1 doses generally cause milder gastrointestinal side effects, but 'microdosing' does not eliminate class risks such as pancreatitis or the thyroid boxed warning, and it is not an FDA-approved protocol.
Effect on side effects
Lower doses often mean milder GI effects, which is much of the appeal. They do not remove the class's serious warnings or contraindications.
The evidence caution
Because below-label regimens are not standardized or well-studied, efficacy at low doses is uncertain and should be monitored by a clinician.
Frequently asked questions
Does microdosing reduce GLP-1 side effects?
Lower doses often reduce gastrointestinal effects, but they do not eliminate the class's serious risks or contraindications.
Sources
- U.S. Food and Drug Administration — labels and safety communications.
- Peer-reviewed clinical trials cited above.
- Our methodology and medical review policy.
How the dates on this page work. Manufacturer self-pay prices were re-read on 15 October 2026: NovoCare’s Wegovy page and Lilly’s Zepbound savings page. Foundayo prices are carried from LillyDirect pages archived 25 September 2026, because lilly.com blocked automated reads. Figures captured from telehealth provider websites carry the date we read that provider’s page, which may be earlier; where it is, the row or a dated notice says so. We do not restamp a figure we have not re-read.